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Abstract
Objective: Polycystic ovarian syndrome (PCOS) refers to an inheritable androgen excess disorder characterized by multiple
small follicles located at the ovarian periphery. Hyperandrogenism in PCOS, and inverse correlation between androgen
receptor (AR) CAG numbers and AR function, led us to hypothesize that CAG length variations may affect PCOS risk.
Methods: CAG repeat region of 169 patients recruited following strictly defined Rotterdam (2003) inclusion criteria and that
of 175 ethnically similar control samples, were analyzed. We also conducted a meta-analysis on the data taken from
published studies, to generate a pooled estimate on 2194 cases and 2242 controls.
Results: CAG bi-allelic mean length was between 8.5 and 24.5 (mean= 17.43, SD= 2.43) repeats in the controls and between
11 and 24 (mean= 17.39, SD= 2.29) repeats in the cases, without any significant difference between the two groups.
Further, comparison of bi-allelic mean and its frequency distribution in three categories (short, moderate and long alleles)
did not show any significant difference between controls and various case subgroups. Frequency distribution of bi-allelic
mean in two categories (extreme and moderate alleles) showed over-representation of extreme sized alleles in the cases
with marginally significant value (50.3% vs. 61.5%, x2 = 4.41; P = 0.036), which turned insignificant upon applying Bonferroni
correction for multiple comparisons. X-chromosome inactivation analysis showed no significant difference in the
inactivation pattern of CAG alleles or in the comparison of weighed bi-allelic mean between cases and controls. Meta-
analysis also showed no significant correlation between CAG length and PCOS risk, except a minor over-representation of
short CAG alleles in the cases.
Conclusion: CAG bi-allelic mean length did not differ between controls and cases/case sub-groups nor did the allele
distribution. Over-representation of short/extreme-sized alleles in the cases may be a chance finding without any true
association with PCOS risk.
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Introduction
Polycystic ovarian syndrome (PCOS) refers to an inheritable
endocrine disorder characterized by multiple small follicles located
under the surface of one or both of the ovaries of a woman. These
follicles are all small and immature and do not grow to maturity
and ovulate. A consensus workshop in Rotterdam in May 2003
suggested that a woman has PCOS if she has two of the following
three features (after the exclusion of related disorders): (1) Oligo- or
an-ovulation, (2) Clinical and/or biochemical signs of hyperan-
drogenism, and (3) Polycystic ovaries [1]. Because the exact
definition of PCOS is still being debated, exact number of women
affected is unknown, but PCOS is the most common cause of
female infertility related to the absence of ovulation (called
anovulatory infertility). Estimates suggest that between 5 and 10
percent of females aged 18 to 44 are affected by PCOS in some
way [2].
PCOS is now considered to be a disorder of androgen excess,
commonly termed as hyper-androgenism [3]. In pathological
conditions, abnormal synthesis of steroids from the ovaries and the
adrenals results in hyperandrogenism. Androgen excess leads to
over activation of the androgen receptor (AR). Human AR gene is
located on the X-chromosome and consists of eight exons and
seven introns. It encodes the AR protein having three domains (1)
N-terminal transactivation domain (2) central DNA-binding
domain and (3) C-terminal ligand- binding domain. The N-
terminal transactivation domain is encoded by exon one harboring
highly polymorphic CAG repeat region. The number of the CAG
repeats may vary from 8 to 35. This microsatellite region (CAG
repeat) encodes a poly-glutamine tract and affects the transactiva-
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tion function of the AR [4]. An in vitro study showed inverse
relationship between the number of CAG repeats and the AR
activity. AR alleles with lesser number of CAG repeats showed
higher activity while increase in the number of CAG repeats
progressively decreased the activity [4].
Variations in the length of the CAG tract have been shown to
affect the risk of various disease conditions [5]. A study on
Barcelona-Spanish girls suggested that shorter CAG repeats
increase androgen sensitivity and subsequent ovarian hyperan-
drogenism, a key feature of PCOS [6]. Association between CAG
and PCOS has been supported by some studies [7–11], but denied
by others [12–16]. A study on Australian Caucasian population
showed that the AR CAG repeat locus and/or its differential
methylation pattern could modulate PCOS phenotype [8]. In view
of strong evidence supporting relation between CAG length and
AR activity, it is reasonable to propose that variation in CAG
repeat numbers may contribute to hyperandrogenism, and hence
to PCOS. We have, therefore, conducted the present study to find
a correlation between CAG length and PCOS risk. Lack of
consensus among published data inspired us to undertake meta-
analysis to build a pooled estimate upon quantitative data
synthesis.
Materials and Methods
Study Population
The study was approved by the Institutional Ethics Committee
of the Centre for Cellular and Molecular Biology, Hyderabad,
India. The analysis was undertaken between May, 2012 and
December, 2012 at the CSIR-Centre for Cellular and Molecular
Biology (CCMB), Hyderabad, and the CSIR-Central Drug
Research Institute, Lucknow, India. In total, 344 subjects with
or without PCOS were recruited from the Genesis Fertility
Research Centre of the Maaruthi Medical Center and Hospitals at
Erode, Tamil Nadu, India. Informed written consent was obtained
from all the participants and all available details about the cases
such as age, height, weight, and age at marriage, were noted. The
inclusion of the patients was done on the basis of the Rotterdam
Revised 2003 (2 out of 3) diagnosis criteria [1]. Hyperandrogenism
was diagnosed by measuring patient’s testosterone, androstenedi-
one, and DHEAS (Dehyroepiandrosteronesulphate) levels, and by
looking at the pattern and extent of terminal hair growth
(hirsutism). Hirsutism was defined as the presence of excess facial
and body hair growth, a male pattern of hair such as over the
upper lip and on the chin, more hair growth than usual on the
arms and legs, and/or hair growth on the chest or extension from
the groin area on to the abdomen and thighs. Hirsutism was
recorded using Ferriman-Gallwey score taking into account the
overall hair growth. Apart from this, menstrual cycle history of the
patients was recorded to diagnose oligo2/ameno-rrhea. Ovarian
morphology was studied by ultrasonography to find if enlarged
ovaries with at least 12 peripherally arranged immature follicles,
characteristic feature of PCOS, were seen.
A total of 169 patients following the above inclusion criteria
were recruited. The exclusion criteria included diagnosis of
congenital adrenal hyperplasia, Cushing’s syndrome, thyroid
dysfunction and hyperprolactinemia. For detailed statistical
analysis, cases were classified into sub-groups based on obesity,
androgenism and hirsutism. Categorization of the patients into
obese and non-obese sub-groups was done according to the World
Health Organization (WHO) criteria. The patients were aged
between 20 and 46 years (mean= 29.70 years, SD=5.07) with
BMI between 22 and 47 kg/m2 (mean= 33.189 kg/m2,
SD=5.892). Out of all cases (N=169), patients having acne,
alopecia aereata and hirsutism were 75, 41, and 117, respectively
(Table 1).
A total of 175 control samples from the same age group as the
patients were collected from ethnically similar proven fertile
women who volunteered for participation in the study. Hospital
staff and women visiting the clinic along with the patients but
having no genetic relationship with the patients, and women
attending the clinic for purposes other than fertility issues (such as
for family planning, vaccination of infants and young children),
were considered as potential controls. The controls were recruited
according to the inclusion criteria of having proven fertility,
normal menstrual cycle and ovarian morphology, and no history
of sub-fertility treatment. Normal ovarian morphology and no
evidence of polycystic ovaries in the controls were confirmed by
transvaginal ultrasonography in 100% of the subjects. Peripheral
blood samples (3–5 ml) from the participants were collected for
genetic analysis. 98.8% of the cases and all controls belonged to
Tamil Nadu and had Dravidian ethnicity, except two cases having
mixed ethnicity.
DNA Isolation
DNA was isolated from the peripheral blood samples according
to the protocol described in our earlier study [17]. DNA
concentration was determined using spectrophotometric method
by reading absorbance at 260 nm, followed by dilution to 10 ng/
ml (working concentration) in standard TE buffer.
PCR Amplification and Genetic Analyses
The CAG repeat region of the AR gene was amplified using
primers and the protocol published in our previous study [17].
Upon amplification, the AR alleles were segregated according to
their size on an ABI 3730 DNA analyzer following the protocol
Table 1. Demographic features of PCOS group.
Parameter No. of cases Mean 6 SD Median Range (Minimum value-Maximum value)
Age (Years) 169 29.70465.073 29 20–46
BMI (kg/m2) 169 33.18965.892 31 22–47
Years of marriage 169 6.15463.461 6.0 1–18
Acne 75/169 – – –
Alopecia aereata 41/169 – – –
Hirsutism 117/169 – – –
Infertility 169/169 – – –
doi:10.1371/journal.pone.0075709.t001
Androgen Receptor CAG Repeat and PCOS Risk
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Figure 1. CAG allele distribution. Frequency distribution of CAG alleles in the PCOS cases and control samples (upper panel), and in obese, non-
obese and control samples (lower panel).
doi:10.1371/journal.pone.0075709.g001
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PLOS ONE | www.plosone.org 3 October 2013 | Volume 8 | Issue 10 | e75709
detailed in our earlier study [17]. PCR amplification and allele
sizing were repeated for all the samples to confirm size of the AR
alleles.
Statistical Analyses
All the comparisons were done using statistical software package
‘‘STATISTICA’’, and the results were confirmed by online
available statistical tools (www.vassarstats.net). The bi-allelic
CAG mean of all controls and all cases were compared by
Student’s independent ‘t’ test. The bi-allelic CAG mean of the
three groups were compared by one factor analysis of variance
(ANOVA), and the significance of mean difference between the
groups was checked by Bonferroni post hoc test after adjusting the
significance for multiple contrasts.
In the second round of analysis, the distribution of cases and
controls in three allele size categories (short, moderate, and long
allele length: ,17, 17–19, .19, respectively) and in two allele size
categories (Extreme and moderate size: ,17 and .19, 17–19,
respectively) was compared. The bi-allelic CAG mean between
groups and lengths were compared by two factors ANOVA, and
the significance of mean difference within and between the groups
was done by Bonferroni post hoc test after adjusting the
significance for multiple contrasts. The frequency distribution
between cases and controls was compared using chi square test.
Two-sided P values of less than 0.05 (95% level of confidence)
were considered significant for inference for individual tests;
however, for multiple comparisons, the significance was checked
against P value corrected for multiple contrasts. The power of all
statistical tests was 80.0% with 5.0% margin of error.
X-chromosome Inactivation Analysis
For X-chromosome inactivation assay, PCR was standardized
using minimum amount of DNA (10 ng per reaction). In case of
heterozygous cases (N=158) and controls (N= 150), 10 ml of the
diluted samples was incubated overnight at 37uC with HPaII in
one set (called digested) and without the enzyme in another set
(called undigested). Next day, the enzyme was inactivated by
heating the mixture at 95uC for 5 minutes. 1 ul of digested and
undigested DNA samples were amplified using primers mentioned
above, followed by calculation of area under each CAG allele
Table 2. Comparison of CAG bi-allelic mean length between
controls and case subgroups.
Groups Subgroups N Mean 6 SD
t/F
value
p*
value
Cases Controls 175 17.4362.43 0.13 0.899
Cases 169 17.3962.29
Obesity Controls 175 17.4362.43 0.85 0.426
Non-obese 25 17.9662.42
Obese 144 17.3062.26
Androgenic Controls 175 17.4362.43 0.60 0.548
Normoandrogenic 82 17.6062.15
Hyperandrogenic 87 17.2062.41
Hirsute Controls 175 17.4362.43 0.31 0.733
Non-hirsute 52 17.6162.21
Hirsute 117 17.3062.33
*For comparison between two groups and three groups, student’s‘t’ test and
ANOVA was done, respectively.
doi:10.1371/journal.pone.0075709.t002
Figure 2. CAG bi-allelic mean distribution. Comparison of bi-allelic mean data in three CAG categories (short, moderate and long alleles)
between cases and controls (a), and between controls and case subgroups based on obesity (b), androgenism (c), and hirsutism (d).
doi:10.1371/journal.pone.0075709.g002
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using GeneMapper software (Applied Biosystems, USA). Total
area under each CAG peak was taken into account for comparison
between digested and undigested samples. The number of
individuals showing inactivation of the longer allele to different
degrees was plotted for cases and controls. Less than 60%
inactivation of any allele was called random inactivation, 60–80%
inactivation of either allele was called non-random inactivation,
and more than 80% inactivation of either allele was called skewed
X-inactivation. X-inactivation weighted bi-allelic mean was
calculated by multiplying the allele length by its percent
inactivation value, followed by addition of the two corrected allele
values.
Meta–analysis
As stated above, published studies have reported contrasting
findings across populations. There could be several plausible
reasons behind this, including ethnic variations as one of the
strongest reasons. Therefore, we have also conducted a meta-
analysis to have a quantitative estimate of the correlation between
CAG repeat length variation and PCOS.
Table 3. Frequency distribution (%) of CAG bi-allelic mean length in three CAG length categories (short, moderate, and long).
Groups Subgroups N
Short CAG
(,17)
Moderate CAG
(17–19)
Long CAG
(.19) x2 value p* value
All Controls 175 55 (31.4) 87 (49.7) 33 (18.9) 5.11 0.078
Cases 169 71 (42.0) 65 (38.5) 33 (19.5)
Obesity Controls 175 55 (31.4) 87 (49.7) 33 (18.9) 6.54 0.162
Non-obese 25 9 (36.0) 9 (36.0) 7 (28.0)
Obese 144 62 (43.1) 56 (38.9) 26 (18.1)
Androgenic Controls 175 55 (31.4) 87 (49.7) 33 (18.9) 5.70 0.223
Normoandrogenic 82 33 (40.2) 34 (41.5) 15 (18.3)
Hyperandrogenic 87 38 (43.7) 31 (35.6) 18 (20.7)
Hirsute Controls 175 55 (31.4) 87 (49.7) 33 (18.9) 5.28 0.260
Non-hirsute 52 22 (42.3) 19 (36.5) 11 (21.2)
Hirsute 117 49 (41.9) 46 (39.3) 22 (18.8)
*Comparison of categorical variable between groups was done by x2test.
doi:10.1371/journal.pone.0075709.t003
Figure 3. CAG bi-allelic mean distribution. Comparison of bi-allelic mean data in two CAG categories (extreme and moderate alleles) between
controls and cases (a), and between controls and case subgroups based on obesity (b), androgenism (c), and hirsutism (d).
doi:10.1371/journal.pone.0075709.g003
Androgen Receptor CAG Repeat and PCOS Risk
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Identification of studies. A systematic literature search in
the public databases; ‘Pubmed’, ‘Google Scholar’ and ‘Science
Direct’, was conducted using the keywords; ‘CAG repeats’,
‘Androgen receptor gene’, ‘AR gene’, ‘Polycystic ovary syndrome’
and ‘PCOS’, in different combinations. Irrelevant studies were
excluded by reading abstracts of the articles. Full texts of all
relevant articles were collected from respective journals or from
the authors by contacting them via e-mail. Citations in these
papers were looked carefully to identify maximum number of
relevant studies. The studies thus selected were further subjected to
inclusion and exclusion criteria, followed by data extraction from
the shortlisted articles.
Inclusion criteria: The following inclusion criteria were adopted
for meta-analysis:
N Each trial should be an independent case-control study.
N The purpose of all the studies should be similar.
N The study had supplied enough information for calculation of
odds ratio.
N Standard methods were used to analyze CAG repeat
polymorphism at high resolution level.
N Inclusion of the patients was done according to standard
diagnosis parameters.
Exclusion criteria: Studies not providing detailed description of
subjects, raw data, and other required information to fully
understand the study design and the data generated were
considered for exclusion.
Data extraction and analysis. Meta-analysis was conducted
using Comprehensive Meta-Analysis software (version-2). Contin-
uous data in the form of mean CAG values (with standard
deviation) and size of case/control groups were fed into the
software. Weighted mean differences (WMD) and 95% confidence
interval were chosen as effect sizes. In two studies [6,18], P values
and sample sizes of cases and controls were used to calculate odds
ratio. Heterogeneity was assessed using Cochran ‘Q’ test. Since
‘Q’ statistics gives an idea about the presence of heterogeneity
qualitatively, I2 value was used to quantify the degree of
heterogeneity between studies. Values for I2 statistics suggested
by Higgins and Thompson were used to infer about the magnitude
Table 4. Frequency distribution (%) of CAG bi-allelic mean length in two CAG categories (extreme and moderate).
Groups Subgroups N Extreme CAG (,17 and .19) Moderate CAG (17–19) x2 value p* value
Cases Controls 175 88 (50.3) 87 (49.7) 4.41 0.036
Cases 169 104 (61.5) 65 (38.5)
Obesity Controls 175 88 (50.3) 87 (49.7) 4.49 0.106
Non-obese 25 16 (64.0) 9 (36.0)
Obese 144 88 (61.1) 56 (38.9)
Androgenic Controls 175 88 (50.3) 87 (49.7) 5.00 0.082
Normoandrogenic 82 48 (58.5) 34 (41.5)
Hyperandrogenic 87 56 (64.4) 31 (35.6)
Hirsute Controls 175 88 (50.3) 87 (49.7) 4.53 0.104
Non-hirsute 52 33 (63.5) 19 (36.5)
Hirsute 117 71 (60.7) 46 (39.3)
*Comparison of categorical variable between groups was done by x2test.
doi:10.1371/journal.pone.0075709.t004
Figure 4. XCI analysis. X-chromosome inactivation analysis showing random, non-random, and skewed inactivation.
doi:10.1371/journal.pone.0075709.g004
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of heterogeneity; viz. 25%, 50% and 75%, which correspond to
low, medium and high heterogeneity, respectively [19]. Publica-
tion bias was evaluated using funnel plot of precision (1/std error
vs differences in means) and Egger’s regression test of significance.
In the absence of significant heterogeneity, Mantel-Haenszel fixed
effect model (Peto method) is recommended, while in presence of
significant heterogeneity, the DerSimonian-Laird random effects
model (DL method) is recommended [20], [21]. We used both
fixed and random effects models to estimate the pooled effect size.
Sensitivity analysis was done by adding the studies in a cumulative
way and by removing one study at a time. In another model of
sensitivity analysis, we removed all the studies using sample size
smaller than 100 in either of the study groups. After sensitivity
analysis, meta-analysis was repeated to select a best-fit model of
meta-analysis.
Results
CAG Mean Length
We found CAG repeat number to lie between 7 and 29 for
both cases and controls. Allele distribution pattern looked
similar between the two groups (Fig. 1). The bi-allelic CAG
mean of controls and cases and case subgroups (non-obese and
obese, normo and hyper-androgenic, and non-hirsute and
hirsute) are summarized in Table 2. The bi-allelic CAG mean
in the controls ranged from 8.5 to 24.5 with mean (6 SD)
value of 17.4362.43 repeats, while in the cases it ranged from
11.0 to 24.0 with mean (6 SD) value of 17.3962.29 repeats.
The median value of bi-allelic mean in controls, cases, and all
subjects (controls+cases) was 18.0 repeats. Comparison of the bi-
allelic mean between controls and cases revealed no significant
difference (t = 0.13, p = 0.899), though the mean lowered by
0.2% in the cases as compared to the controls. Further, one
way ANOVA revealed similar bi-allelic CAG mean without
significant difference between controls and case subgroups based
on obesity (F = 0.85, p = 0.426), androgenism (F= 0.60,
Figure 5. PRISMA flow diagram. A systematic flow diagram showing inclusion and exclusion of studies for meta-analysis.
doi:10.1371/journal.pone.0075709.g005
Androgen Receptor CAG Repeat and PCOS Risk
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p= 0.548), and hirsutism (F= 0.31, p = 0.733); though it lowered
by 0.7%, 1.3% and 0.7% in obese, hyper-androgenic and
hirsute cases, respectively, and showed 3.0%, 1.0% and 1.0%
increase in non-obese, normoandrogenic and non-hirsute cases,
respectively, in comparison to the controls.
CAG Bi-allelic Mean Distribution
Short/moderate/long allele size. While considering CAG
bi-allelic mean a continuous variable, the bi-allelic mean was
categorized in three groups (short: CAG ,17, moderate: CAG
17–19, and long: CAG .19) on the basis of median cut off
value of 18.0. Two way ANOVA was employed for comparing
bi-allelic CAG mean between the three groups, showing no
significant difference between controls and cases (F = 3.25,
p = 0.072), and between controls and case subgroups based on
obesity (F= 1.95, p= 0.144) and hirsutism (F= 2.14, p= 0.119)
(Fig. 2). A significant difference between controls and case
subgroups based on androgenism was observed (F = 3.67,
p = 0.027); nevertheless, the difference was not seen in post-
hoc analysis comparing normoandrogenic and hyperandrogenic
case subgroups with the controls.
Further, the numbers of subjects (frequency distribution)
falling in the three categories of bi-allelic mean were compared
between controls and cases, and between controls and various
case subgroups (Table 3). It was found that 10.6% more of the
cases (42.0%) had short CAG alleles than controls (31.4%), but
almost equal number of the cases (19.5%) and controls (18.9%)
had bi-allelic mean more than nineteen. However, comparison
of the frequency between cases and controls showed no
significant difference (x2 = 5.11, p= 0.078). Similarly, no signif-
icant difference between controls and various case subgroups
based on obesity (x2 = 6.54, p = 0.162), androgenism (x2 = 5.70,
p = 0.223), and hirsutism (x2 = 5.28, p = 0.260), was observed
(Table 3). Nevertheless, 11.7% more of obese cases (43.1%),
12.3% more of hyperandrogenic cases (43.7%), and 10.5%
more of hirsute cases (41.9%) had shorter alleles as compared to
the controls (31.4%). Further, the bi-allelic CAG mean length
frequency for short alleles (,17 repeats) showed a linear trend
of increase from controls to cases (x2 = 1.60, p = 0.206), and
from controls to case-subgroups (obesity: x2 = 6.54, p = 0.162;
androgenism: x2 = 5.70, p = 0.223); however, the differences did
not reach statistical significance in any of these comparisons.
Extreme and moderate allele size. In another method of
analysis, the bi-allelic mean was categorized into two groups
(extreme: CAG ,17 and .19, and moderate: CAG 17–19). Two
way ANOVA was employed for comparison of the bi-allelic CAG
mean between the cases and the controls. However, no significant
difference between cases and controls (F = 0.08, p = 0.783) and
between controls and case sub-groups based on obesity (F = 0.57,
p = 0.565), androgenism (F= 0.34, p = 0.710), and hirsutism
(F= 0.35, p = 0.707), was observed (Fig. 3).
Further, the numbers of subjects falling in the two CAG
categories were compared between controls and cases, and
between controls and various case subgroups (Table 4). It was
found that 11.2% more of the cases (61.5%) had extreme CAG
alleles than controls (50.3%) and the comparison produced P value
less than 0.05 (P= 0.036); however, Bonferroni correction for
multiple comparisons rendered it insignificant. It was found that
10.8% more of obese cases (61.1%), 14.1% more of hyperandro-
genic cases (64.4%), and 10.4% more of hirsute cases (60.7%) had
extreme CAG alleles as compared to the controls (50.3%).
However, the distribution of the subjects did not differ significantly
between controls and case subgroups based on obesity (x2 = 4.49,
p = 0.106), androgenism (x2 = 5.00, p= 0.082), and hirsutism
(x2 = 4.53, p = 0.104) (Table 4). Moreover, the bi-allelic CAG
mean length frequency for extreme sized alleles showed a linear
trend of increase from controls to hyperandrogenism through
normoandrogenism with significant value (x2 = 4.96, p= 0.026).
Table 5. Published data extracted for meta-analysis.
Cases Controls
Studies for meta-analysis Population Size Mean Std dev Size Mean Std dev P value*
Mifsud et al, 2000 Singaporean 91 22.97 0.24 112 23.09 0.23
Hickey et al, 2002 Australian Caucasian 122 23 2.025 83 22.34 2.094
Ibanez et al, 2003 Barcelona girls (Spain) 181 21.3 NA 124 22 NA 0.003
Jaaskelainen et al, 2005 Finnish 106 21.5 2.2 112 21.5 2.1
Ferk et al, 2008 Slovene population, Slovenia 102 22.4 3.5 110 21.9 3.5
Kim et al, 2008 South Korean 114 23.3 1.8 205 23.1 2
Liu et al, 2008 Han Chinese (Shanghai) 148 22.88 1.76 104 22.85 1.6
Shah et al, 2008 (1) American white population 270 21.8 3.1 165 22.3 3.11
Shah et al, 2008 (2) American black population 37 20.1 3.44 84 20.2 3.08
Van et al, 2008 Belgium Caucasian population 97 21.93 2.122 31 21.823 3.112
Dasgupta et al, 2010 South Indian 250 18.74 0.13 299 18.73 0.12
Laisk et al, 2010 Europe Caucasian 32 21.5 1.6 79 21.6 1.8
Radian et al, 2010 Europe Caucasian 137 22.58 NA 130 23.16 NA 0.01
Robeva et al, 2010 Bulgaria Caucasian 52 21.6 2.62 41 21.3 3.71
Schuring et al, 2011 German 72 21.43 1.87 179 21.99 2.07
Skrgatic et al, 2011 Croatian women 214 22.1 3.4 209 21.9 3.2
Present study, 2012 South Indian 169 17.4 3.3 175 17.4 3.31
*Shown only when P value was manually fed into the software.
doi:10.1371/journal.pone.0075709.t005
Androgen Receptor CAG Repeat and PCOS Risk
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Figure 6. Meta-analysis. Forest plot for pooled data analysis (upper panel), forest plot after removal of studies using sample size less than 100
(middle panel), and funnel plot of precision by difference in means for publication bias (lower panel).
doi:10.1371/journal.pone.0075709.g006
Androgen Receptor CAG Repeat and PCOS Risk
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X-chromosome Inactivation Analysis
X-chromosome inactivation analysis showed that random X-
inactivation was most common (76% of the cases and 74% of the
controls) (Fig. 4). Non-random inactivation was seen in 19% of the
cases and 23% of the controls. Skewed X-inactivation was
observed in 5% of the cases and 3% of the controls. The
difference in the inactivation was not statistically significant.
Among the individuals showing non-random inactivation, smaller
alleles were preferentially active in the cases, but the differences
were not significant (P = 0.512). Further, the weighed bi-allelic
mean was not significantly different between cases and controls
(P = 0.791).
Meta-analysis
Literature search. Literature search retrieved twenty-two
studies, of which only fifteen studies fulfilled the inclusion criteria.
Among the remaining seven studies, two [11,22] were excluded
due to lack of full text article, four [2,4,10,17] due to irrelevant
data, and one [23] due to lack of information required for meta-
analysis. For Shah et al (2008), we used two separate data sets
(Black and White populations) in meta-analysis. For Hickey et al
(2002), mean CAG repeat length for each subject was determined
from the allele frequency graph for cases and controls. Thus, along
with the present study from India, this meta-analysis included data
from sixteen studies (seventeen groups) for a total of 2194 cases
and 2242 controls (Fig. 5, Table 5).
Quantitative data synthesis. Out of seventeen studies,
seven reported short CAG alleles in the cases in comparison to
the controls [6,7,9,18,24,25], of which four found the differences
to be significant (Fig. 6) [6,7,18,25]. Out of the remaining studies,
eight showed longer CAG allele in cases [8,13–16,26–28], but
there was only one study finding the differences to be significant
[8]. Remaining two studies (Jaaskelainen et al, 2005 and the
Present study) did not find any significant difference in mean CAG
length between cases and controls (Fig. 6).
Looking at the expected heterogeneity across the studies, we
had a priori preference to use random effects model for overall
inference. Comparison of data showed true significant heteroge-
neity (Q-value = 43.88, df (Q) = 16.000, P-value = 0.00, I-
squared= 63.538) between studies, favoring the use of random
effects model. Pooled estimate of the weighted mean difference
across the studies showed no statistically significant difference
(random effects model; mean difference =20.084, 95%
CI=20.203 to 0.035, P = 0.166) (Fig. 6 and Table 6); however,
the mean CAG value for cases was shorter than controls.
Symmetrical distribution of the studies on precision plot suggested
absence of publication bias (Fig. 6). Further, Egger’s regression test
confirmed the absence of publication bias (two tailed p
value = 0.352).
Sensitivity analysis removing one study at a time failed to
identify any study sensitive enough to severely affect the pooled
estimate. After removal of seven studies using small sample size
(Hickey et al. 2002, Laisk et al. 2010, Mifsud et al. 2000, Robeva
et al. 2010, Shah et al. 2008, Schuring et al. 2011 and Van et al.
2008), data became more homogeneous (Q-value = 20.991, df
(Q) = 9.000, P-value = 0.013, I-squared = 57.125). However, the
overall inference that the cases had short CAG alleles in
comparison to the controls, but without statistical significance
(random effects model; mean difference =20.115, 95%
CI=20.321 to 0.090, P= 0.271), remained unaffected.
Discussion
Hyperandrogenism in a large fraction of the PCOS cases
suggests involvement of androgens and the AR gene in the etiology
of this disorder. Variations in the number of CAG repeats in the
coding region of the AR gene make it an interesting polymorphism
for investigation. In vitro demonstration of the effect of CAG length
on AR function has infused further interest in deciphering the
impact of repeat length on ovarian function. Our analysis on a
large sample size from South India found that the mean CAG
length does not significantly differ between cases and controls;
nevertheless a trend of higher frequency of extreme sized alleles in
the cases in comparison to the controls was seen. Increased PCOS
risk with short CAG is supported by an almost equal number of
studies [9–11,22] as many studies deny any such correlation [7,12–
16]. At least one study suggested increased risk with an increase in
CAG length [8]. To precisely uncover the differences in the alleles
distribution between cases and controls, we analyzed AR alleles for
X-chromosome inactivation (XCI) pattern on the basis of Lyon
hypothesis [8,9,16]. We found a little higher percentage of active
short alleles in the cases showing non-random inactivation;
however, statistical comparison revealed no significant difference
in either the allele distribution or the mean repeat length. Hickey
et al (2002) observed a greater incidence of non-random XCI
pattern in PCOS group in comparison to the controls. However,
the difference was not statistically significant. According to
Dasgupta et al (2010), short alleles are preferentially active among
PCOS cases with non-random XCI pattern [16]. Interestingly,
they also did not find any significant difference in the XCI pattern
between cases and controls.
Obesity is thought to promote the development of PCOS [29].
Therefore, we categorized the patients according to their BMI
Table 6. Summary of meta-analysis results.
Meta-analysis
Effect
Models WMD CI P value Heterogeneity
Publication bias
(P value)*
Lower Upper I2 value (P value)
When all eligible studies
were included
Fixed 20.004 20.024 0.015 0.671 63.53 (0.00) No (0.352)
Random 20.084 20.203 0.035 0.166
After removing studies
having sample size ,100
in any of group
Fixed 0.007 20.013 0.028 0.48 57.12 (0.013) No (0.327)
Random 20.115 20.321 0.09 0.271
*indicates Egger’s regresstion test two tailed p value.
doi:10.1371/journal.pone.0075709.t006
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values and performed group-wise analysis of allele data. In subset
analysis, mean CAG length in the obese and non-obese groups was
not significantly different from controls, suggesting that obesity in
PCOS cases is not significantly associated with CAG repeat length
variation. We observed higher frequency of short CAG repeats in
PCOS obese women; however, comparison between obese and
non-obese groups should be taken with caution due to very small
sample size in one of the groups. Nevertheless, another study
reported increased significant odds of PCOS in obese women
having extreme sized CAG alleles (,18 and .20 repeats) [16].
Our findings further strengthen the proposal that variation in the
CAG length on either side of moderate allele length may increase
PCOS risk. It is important to note that the comparison of mean
CAG value did not show any difference between the experimental
groups. The importance of analyzing the allele distribution instead
of mean length has been emphasized previously [30,31]; however,
comparison of allele distribution also did not show any significant
difference between cases and controls.
Contrast in the results across the studies could be due to the
ethnic/racial and study-to-study variations in the recruitment of
cases and controls. For example, before 2003 Rotterdam criteria,
there was a wide variation in diagnostic criteria of PCOS, and
1990 NIH criteria, which does not include the appearance of
polycystic ovaries, were most often used for diagnosis of PCOS
condition. Wide variation in the outcome of published studies
prompted us to undertake meta-analysis to generate a pooled
estimate of correlation between CAG length and the PCOS risk.
Seventeen studies adding to a total of 2194 cases and 2242 controls
were included in the meta-analysis. Pooled estimate found
significant heterogeneity in the data and suggested that the mean
length between cases and controls does not differ significantly,
though a minor over-representation of shorter alleles in the cases
was evident. Sensitivity analysis failed to identify any study
sensitive enough to significantly modify the results of meta-
analysis. Two other recent meta-analyses have also stated no
association of the CAG repeat with PCOS risk [32,33]. However,
a population/region specific meta-analysis has not been conducted
due to lesser number of studies available on different ethnic
populations. With publication of more original studies, a
population wise meta-analysis would be desirable in order to
uncover ethnic specific differences, if any.
The results of this meta-analysis could be affected by some
variables such as clinical and phenotypic features of subjects;
which could have affected the recruitment of cases across studies.
We could not adjust the pooled estimate for these limitations
because of different reporting approaches used in the studies.
However, such an adjustment could provide more comprehensible
estimate of the relationship between CAG length and PCOS risk,
particularly in the subgroup analysis. Since the studies using small
sample size are more likely to show odd outcomes, inclusion of
small studies could have affected the pooled estimate. Seven
studies had used a sample size ,100 in either of the groups.
Interestingly, after excluding such studies, only two were found to
have reported significant association [6,18]. Therefore, further
analysis on large cohorts on ethnically divergent populations is
encouraged. Further, exclusion of the studies not fitting our
inclusion criteria could have affected the overall inference of this
meta-analysis.
In summary, our study on a South Indian population and meta-
analysis on seventeen studies constituting a large cohort found no
significant difference between cases and controls. A little higher
frequency of short/extreme-sized alleles in the cases may be a
chance finding, without any real implication in PCOS pathogen-
esis. Most of the earlier studies have compared mean CAG length
between cases and controls. This was due to a general belief that
AR activity is inversely proportional to the CAG length. This
assumption is based on a few studies comparing AR alleles with
great differences in CAG lengths. Recent in vitro studies have
shown that AR activity is maximum in moderate sized alleles
compared with short and long alleles [30]. Averaging the allele
length may dilute the differences in the distribution of extreme
sized alleles. This is further strengthened by a recent stratified
analysis on CAG length, showing increased odds of male infertility
with short and long CAG alleles in comparison to moderate allele
size [31]. Moderate allele sizes must have become frequent in the
population as a result of better fitness; therefore, it is logical to
analyze data to look for differences in the distribution of extreme
sized (too long and too small) alleles, assuming a non-linear
relationship between CAG numbers and AR function. Availability
of allele distribution data would help undertake meta-analysis to
find if differential allele distribution affects PCOS risk. At present,
it can be concluded that mean CAG length does not affect PCOS
risk; however, a meta-analysis on distribution data could help turn
the last stone before we end up concluding existence of no
association between CAG length and PCOS risk.
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